Search results
13 maj 2020 · Argon laser trabeculoplasty (ALT) was once the gold standard laser treatment for open-angle glaucoma (OAG), but it is poorly suited to repeat treatments because of significant coagulative damage and disruption to the trabecular meshwork architecture. 2, 3 Latina et al 4 first described
Conclusion: Argon laser trabeculoplasty is an effective means for reducing IOP in many patients followed for an extended time. However, up to one half of eyes within 5 years of ALT and two thirds of eyes within 10 years may require additional laser or surgical intervention for glaucoma control.
Long-term efficacy of 360° argon laser trabeculoplasty was studied in 118 eyes of 93 patients with uncontrolled chronic open-angle glaucoma. The mean intraocular pressure (IOP) decrease was 8.9 ± 5.4 mmHg (mean ± standard deviation [SD] in 71 eyes at 1 year, 9.3 ± 4.3 mmHg (mean ± SD) in 51 eyes at 3 years, and 10.3 ± 3.9 mmHg (mean ± SD ...
Argon laser peripheral iridoplasty (Visulas 532s; Carl Zeiss Meditec, Germany) was performed under topical anesthesia using an Abraham lens (Ocular Instruments, Inc.) with a spot size that initially was set at 500 μm, with power (150–400 mW) and duration (0.4–0.5 seconds) titrated based on response. 18 Burns were aimed at the iris root ...
5 kwi 2021 · For many years, the Argon blue-green laser with spectral peaks at 488 nm (blue) and 514 nm (green) was the most widely used ophthalmic laser for such applications as photocoagulation of extrafoveal choroidal neovascular membranes to treat age-related macular degeneration, pan-retinal photocoagulation (PRP) to treat DR, and for sealing breaks to ...
1 wrz 1993 · Conclusion: Argon laser trabeculoplasty is an effective means for reducing IOP in many patients followed for an extended time. However, up to one half of eyes within 5 years of ALT and two thirds of eyes within 10 years may require additional laser or surgical intervention for glaucoma control.
To analyze reduction of intraocular pressure (IOP) by argon laser trabeculoplasty (ALT) in the Early Manifest Glaucoma Trial and factors influencing the effect of such treatment.
